DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Status:
Recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as
Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory
Medulloblastoma.